| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Feb―06 |
Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients |
Monique M.R. de Maat, Henk J. van Leeuwen, Lian Roovers, Sabine J.G.M. Ahlers, Jolanda Lambers, Marcel M.C. Hovens |
| 2 |
[GO] |
2023―Sep―27 |
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study |
Paul Thoueille, Margot Delfraysse, Pascal Andre, Thierry Buclin, Laurent A. Decosterd, Chiara Fedeli, et al. (+3) Pilar Ustero, Alexandra Calmy, Monia Guidi |
| 3 |
[GO] |
2023―Jun―15 |
Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial |
Dawei Yang, Minjie Ju, Hao Wang, Yichen Jia, Xiaodan Wang, Hao Fang, Jia Fan |
| 4 |
[GO] |
2022―Dec―02 |
Potential antiviral peptides targeting the SARS-CoV-2 spike protein |
Ibrahim Khater, Aaya Nassar |
| 5 |
[GO] |
2022―Jan―17 |
Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study |
Jimyung Park, Seng Chan You, Jaehyeong Cho, Chan Hyuk Park, Woon Geon Shin, Rae Woong Park, Seung In Seo |
| 6 |
[GO] |
2021―Oct―21 |
Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19 |
Maral Aminpour, Williams Ernesto Miranda Delgado, Soren Wacker, Sergey Noskov, Michael Houghton, D. Lorne J. Tyrrell, Jack A. Tuszynski |
| 7 |
[GO] |
2021―Oct―13 |
COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia |
Elly Nurus Sakinah, Muhammad Yuda Nugraha, Tegar Syaiful Qodar, Bagus Wahyu Mulyono, Achmad Ilham Tohari |
| 8 |
[GO] |
2021―Mar―11 |
Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19 |
Margaux Lafaurie, Guillaume Martin-Blondel, Pierre Delobel, Nassim Kamar, Sandrine Charpentier, Agnès Sommet, Guillaume Moulis |
| 9 |
[GO] |
2020―Sep―03 |
A protein interaction map identifies existing drugs targeting SARS-CoV-2 |
Claudia Cava, Gloria Bertoli, Isabella Castiglioni |
|
